Literature DB >> 8925804

Effect of a high-protein meal on gabapentin pharmacokinetics.

B E Gidal1, M M Maly, J Budde, G L Lensmeyer, M E Pitterle, J C Jones.   

Abstract

The anticonvulsant gabapentin is transported across biological membranes via the L-amino acid transport system (System-L). Absorption of gabapentin is saturable, and in-vitro data have previously demonstrated that both L-leucine and L-phenylalanine may compete with the intestinal transport of gabapentin. The purpose of this study therefore was to determine whether a high-protein meal would interfere with gabapentin absorption. Ten healthy volunteers received in a randomized, cross-over design, a single 600-mg dose of gabapentin in the fasting state and after a high-protein meal consisting of 80 gm total protein (4.1 g phenylalanine, 8.2 g leucine and 4.2 g isoleucine), 52 g carbohydrate, and 9 g fat. Plasma gabapentin concentrations were measured by HPLC at baseline, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 30 h. Calculated pharmacokinetic parameters included Cmax' Tmax' AUC and T1/2. In addition, a pharmacodynamic assessment (using visual analog scales) of gabapentin-related adverse effects was performed at 2 h post drug ingestion and was compared between study phases. Statistical analysis included Student's t-test for paired data, with significance assigned at P < 0.05. Cmax was significantly increased by 36% (3.87 +/- 1.15 vs 5.28 +/- .97 micrograms/ml, P = 0.002), and Tmax tended to be shorter (3.9 +/- 1.8 vs 2.8 +/- .35 h, P = 0.10), after the high-protein meal. Although AUC was increased by 11%, this did not achieve statistical significance. Despite significantly higher plasma concentrations at 2 h, subjects reported significantly fewer adverse effects after the high-protein meal. Potential mechanisms to explain these unexpected findings may be that the large amino acid load delivered with the high-protein meal enhanced gabapentin absorption via trans-stimulation, the process by which acutely increased intestinal luminal amino acid concentrations result in an acute up regulation in System-L activity. Conversely, the decrease in perceived adverse CNS effects of gabapentin following the high-protein meal may reflect CNS competition for System-L transport.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8925804     DOI: 10.1016/0920-1211(95)00051-8

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  10 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  PEPT1 enhances the uptake of gabapentin via trans-stimulation of b0,+ exchange.

Authors:  Theresa V Nguyen; David E Smith; David Fleisher
Journal:  Pharm Res       Date:  2006-12-28       Impact factor: 4.200

Review 3.  A Review of Food-Drug Interactions on Oral Drug Absorption.

Authors:  Jianyuan Deng; Xiao Zhu; Zongmeng Chen; Chun Ho Fan; Him Shek Kwan; Chi Ho Wong; Ka Yi Shek; Zhong Zuo; Tai Ning Lam
Journal:  Drugs       Date:  2017-11       Impact factor: 9.546

Review 4.  A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin.

Authors:  Howard N Bockbrader; David Wesche; Raymond Miller; Sunny Chapel; Nancy Janiczek; Paula Burger
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

5.  Meta-analyses of dose-exposure relationships for gabapentin following oral administration of gabapentin and gabapentin enacarbil.

Authors:  Chao Chen
Journal:  Eur J Clin Pharmacol       Date:  2013-06-07       Impact factor: 2.953

6.  In vivo effects of glycyl-glutamate and glycyl-sarcosine on gabapentin oral absorption in rat.

Authors:  Theresa V Nguyen; David Fleisher; David E Smith
Journal:  Pharm Res       Date:  2007-03-23       Impact factor: 4.200

Review 7.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 8.  Gabapentin: in postherpetic neuralgia.

Authors:  Monique P Curran; Antona J Wagstaff
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

9.  A comparative study of the pharmacokinetics of traditional and automated dosing/blood sampling systems using gabapentin.

Authors:  Bijay Aryal; Kim Tae-Hyun; Kim Yoon-Gyoon; Kim Hyung-Gun
Journal:  Indian J Pharmacol       Date:  2011-05       Impact factor: 1.200

10.  Gabapentin: An update of its pharmacological properties and therapeutic use in epilepsy.

Authors:  Azim Honarmand; Mohammadreza Safavi; Mohammad Zare
Journal:  J Res Med Sci       Date:  2011-08       Impact factor: 1.852

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.